Literature DB >> 1088110

Medical management of mycetoma.

E S Mahgoub.   

Abstract

A number of drugs and drug combinations were tested both in vitro and in vivo against pathogens causing actinomycetoma and maduromycetoma. Of 144 patients with actinomycetoma treated, 63.2% were cured, 21.5% showed great improvement in their condition, and 11.1% showed some improvement. Treatment was successful even when there was advanced bone involvement. The most effective treatments involved dapsone plus streptomycin sulfate or sulfamethoxazole-trimethoprim plus streptomycin. Sulfadoxine-pyrimethamine plus streptomycin or rifampicin plus streptomycin also gave good results. Griseofulvin plus penicillin showed some promise in the management of maduromycetoma caused by Madurella mycetomi but at the present time this should be used only as an adjunct to surgery. All mycetoma patients undergoing drug therapy should be carefully monitored and treatment should be temporarily suspended if anaemia or leucopenia develop.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1088110      PMCID: PMC2366579     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  5 in total

1.  [Sensitivity of the causative agents of fungal mycetomas to griseofulvin and amphotericin B].

Authors:  E DROUHET; G SEGRETAIN
Journal:  Bull Soc Pathol Exot Filiales       Date:  1960 Sep-Oct

2.  Black grain maduromycosis caused by Madurella grisea; report of the first North American case and its response to therapy with diaminodiphenylsulfone.

Authors:  E NEUHAUSER
Journal:  AMA Arch Derm       Date:  1955-12

3.  Treatment of nocardial infection with trimethoprim-sulphamethoxazole.

Authors:  E R Pavillard
Journal:  Med J Aust       Date:  1973-06-30       Impact factor: 7.738

4.  Plasma concentrations of griseofulvin in human volunteers.

Authors:  D S Platt
Journal:  Br J Dermatol       Date:  1970-09       Impact factor: 9.302

5.  [Clinical aspects and therapy of mycetoma].

Authors:  P Lavalle
Journal:  Dermatol Int       Date:  1966 Apr-Jun
  5 in total
  9 in total

1.  An anterior mediastinal mass with draining sternal sinus tracts due to Nocardia braziliensis.

Authors:  D M Kroe; N Shulman; C M Kirsch; J H Wehner
Journal:  West J Med       Date:  1997-07

2.  Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin.

Authors:  Amit M Sharma; Namita Sharma; Amritpal Nat; Meghan Rane; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2014-10-27       Impact factor: 2.345

3.  Mycetoma of thumb caused by Nocardia transvalensis.

Authors:  H C Gugnani; J O Ojukwu; A V Suseelan
Journal:  Mycopathologia       Date:  1982-10-22       Impact factor: 2.574

4.  Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review.

Authors:  Saira B Momin; Blakely S Richardson; Michael G Bryan; James Q Del Rosso; Narciss Mobini
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

Review 5.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

6.  In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis.

Authors:  Alejandra Gomez-Flores; Oliverio Welsh; Salvador Said-Fernández; Gerardo Lozano-Garza; Roman Erick Tavarez-Alejandro; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Actinomycotic mycetoma of the thigh.

Authors:  I F Roberts; Q N Karim; R D Rosin
Journal:  J R Soc Med       Date:  1989-09       Impact factor: 18.000

Review 8.  The mycetoma knowledge gap: identification of research priorities.

Authors:  Wendy W J van de Sande; El Sheikh Maghoub; Ahmed H Fahal; Michael Goodfellow; Oliverio Welsh; Ed Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

Review 9.  Mycetoma: An Update.

Authors:  Vineet Relhan; Khushbu Mahajan; Pooja Agarwal; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.